International Journal of Cancer

HKG Epitherapeutics Publishes New Data on epiCervix Test, Showing Ability to Detect Cervical Cancer Earlier than Traditional Screening Methods

Retrieved on: 
Tuesday, August 22, 2023
Survival rate, DNA, Tooth, Anxiety, PAP, Survival, DPP10, Cancer, Ageing, Cervical cancer, Woman, CA10, International Journal of Cancer, Cell, Death, Professor, The Company, Patient, Rated R, Canadian International Council, McGill University, HPV, DNA methylation, Principal, Gene, HAS1, Birth control, Papanikolaou, HKG

HONG KONG, Aug. 22, 2023 /PRNewswire/ -- HKG Epitherapeutics ("HKG" or the "Company"), a commercial-stage biotech company developing novel tools for the early detection of cancer and promoting healthy aging, in collaboration with McGill University, announced today that the International Journal of Cancer has published new data on the ability of the Company's proprietary epiCervix test to detect cervical cancer in patients sooner compared to traditional screening methods, including manual laboratory cell examination from Papanicolaou (Pap) smears and human papillomavirus (HPV) testing.

Key Points: 
  • As cervical cancer remains the fourth most common type of cancer among women globally , the World Health Organization calls for women to be screened regularly with a high-performance test.
  • In 2020 alone, there were approximately 604,000 new cases and 342,000 deaths due to cervical cancer.
  • Through integrating epiCervix into the current screening process, we can make cervical cancer no different for women than needing to get a tooth extracted."
  • HKG's epiCervix test can detect cervical cancer at its earliest stages by looking at changes in four specific genes.

SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived Immunotherapy

Retrieved on: 
Monday, October 3, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Frontiers, Vulva, VP, Centers for Disease Control and Prevention, Cancer, Human papillomavirus infection, CD8, U.S. Securities and Exchange Commission, Technology, Risk, SQZ, Immunotherapy, Research, Eryptosis, Private Securities Litigation Reform Act, Man, E6, Virus, Autoimmunity, HPV, Center, COVID-19, Annual report, Infection, Cisplatin, Translation, Immune tolerance, Addition, International Journal of Cancer, Penis, Ageing, Animal, Red blood cell, APC, CDC, NYSE, Canadian International Council, AACS, Confidentiality, AAC, Patient, Cell, Degenerative disease, Publication, Woman, RBC, Therapy, Antigen, Vaccine, Pharmaceutical industry, E7, Immunology

SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of preclinical research on the SQZ Activating Antigen Carrier (AAC) platform.

Key Points: 
  • SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of preclinical research on the SQZ Activating Antigen Carrier (AAC) platform.
  • This paper demonstrates the potential of our technology to generate an effective red blood cell-derived cancer immunotherapy, said Howard Bernstein, M.D., Ph.D., Chief Scientific Officer at SQZ Biotechnologies.
  • We are excited about the preclinical findings of our AAC program, which has shown potential in both monotherapy settings and in combination with chemotherapy, said Scott Loughhead, Ph.D., VP of Translational Research at SQZ Biotechnologies.
  • SQZ AACs are generated by squeezing red blood cells (RBCs) with antigens and activating adjuvant.

SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell Activation

Retrieved on: 
Tuesday, July 12, 2022
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Cell engineering, Centers for Disease Control and Prevention timeline, Vulva, EBV, Autoimmunity, Annual report, DLT, Patient, MD, TP53, Private Securities Litigation Reform Act, Â, European Society of Gene and Cell Therapy, Woman, Cancer, Infection, U.S. Securities and Exchange Commission, Confidentiality, PD-1, International Journal of Cancer, Risk, Cell, Degenerative disease, Virus, E7, APC, CDC, Human papillomavirus infection, NK, MHC, Immune tolerance, Safety, Tumor microenvironment, Center, Penis, COVID-19, Therapy, Neoplasm, FDA, Canadian International Council, E6, NYSE, CD8, Man, Comparison, Oncology, KRAS, Review, Congress, Monocyte, Research, SQZ, HPV, Publication, Vaccine, Medical imaging, Pharmaceutical industry, Technology

Published in ESMOs Immuno-Oncology and Technology (IOTECH) journal, the review further explores the advantages of the companys Cell Squeeze technology in cell engineering and manufacturing as well as potential opportunities to develop additional clinical candidates with enhanced capabilities.

Key Points: 
  • Published in ESMOs Immuno-Oncology and Technology (IOTECH) journal, the review further explores the advantages of the companys Cell Squeeze technology in cell engineering and manufacturing as well as potential opportunities to develop additional clinical candidates with enhanced capabilities.
  • We look forward to potentially building on these early results through combination with various immunomodulatory drugs, such as checkpoint inhibitors.
  • SQZ has three ongoing Phase 1/2 clinical trials aiming to drive CD8 T cell responses against HPV16+ solid tumors.
  • SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases.

SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors

Retrieved on: 
Wednesday, April 27, 2022
Oncology, Health, FDA, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Publication, U.S. Securities and Exchange Commission, NYSE, Virus, Immune tolerance, Cell, SQZ, Confidentiality, Cancer, E7, Patient, Human papillomavirus infection, FDA, Risk, DLT, HPV, Fast track (FDA), Private Securities Litigation Reform Act, COVID-19, Degenerative disease, Food, Vulva, ESMO, APC, Penis, Autoimmunity, Therapy, Annual report, Woman, CDC, E6, Research, Doctor of Philosophy, Canadian International Council, Review, Center, International Journal of Cancer, Centers for Disease Control and Prevention, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Infection, Safety, Man, Pharmaceutical industry, Vaccine

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the companys lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors.

Key Points: 
  • SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the companys lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors.
  • We are thrilled to receive FDA Fast Track Designation for our SQZ Antigen Presenting Cells product candidate, said Armon Sharei, Ph.D., Chief Executive Officer and Founder at SQZ Biotechnologies.
  • The FDA Fast Track program can potentially expedite future review processes and accelerate the registrational path for SQZ-PBMC-HPV.
  • SQZ-PBMC-HPV is being evaluated in a Phase 1/2 clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors.

Bionano Genomics Announces Publication of Prospective Study Demonstrating Performance Improvements from OGM in the Analysis of AML and MDS Compared to Traditional Methods

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, Risk, FISH, Hospital Insurance and Diagnostic Services Act, Karyotype, Method, In situ hybridization, International Journal of Cancer, University Hospitals of the Ruhr-University of Bochum, Autism, Canadian International Council, Security (finance), Lineagen, Fluorescence, University, Annual report, ELN, Genomics, COVID-19, AML, Genome, Company, Biology, Medicine, Lymphatic system, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Adoption, Acute myeloid leukemia, OGM, SAN, Classification, Forward-looking statement, Patient, MDS, Solution, SVS, Research, Myelodysplastic syndrome, Doctor of Philosophy, Software, Medical device

The authors describe how OGM detected 31% more European Leukemia Net (ELN) and recurrent myeloid abnormalities compared to karyotyping and FISH.

Key Points: 
  • The authors describe how OGM detected 31% more European Leukemia Net (ELN) and recurrent myeloid abnormalities compared to karyotyping and FISH.
  • OGM also found abnormalities in 35% more cases than karyotyping and FISH, and in 67% of samples, the karyotype could be redefined by OGM.
  • The authors also found the cost-efficiency of using a single OGM analysis, with OGM cost comparable to two FISH probes.
  • We believe this research demonstrates the usability of OGM for analysis of AML and MDS.

PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy

Retrieved on: 
Monday, January 10, 2022
SEC, Safety, MD Anderson Cancer Center, Colon, Composition, United States Patent and Trademark Office, HPV16, National, Infection, Goal, Patient, Merck, Nature, Use, HPV, Canadian International Council, Immune system, Cancer, Merck & Co., International Journal of Cancer, Lung, Forward-looking statement, Incidence, Partnership, NCI, Food, Patent, Research, Review, Food and Drug Administration, Immunotherapy, Company, Prostate, Risk, National Cancer Institute, Nasdaq, PDSB, Technology, Neck, Cervical cancer, Communication, Biotechnology, USPTO, Breast, COVID-19, University, Twitter, GLOBE, Head, Method, University of Texas at Austin, Pharmaceutical industry, Vaccine

FLORHAM PARK, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that it has been granted U.S. Patent Application No.

Key Points: 
  • FLORHAM PARK, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that it has been granted U.S. Patent Application No.
  • 15,724,818 titled Novel HPV16 Non HLA-Restricted T-cell Vaccines, Composition and Methods of Use Thereof by the United States Patent and Trademark Office (USPTO).
  • The newly issued patent covers the PDS0101 immunotherapy which consists of a combination of the Versamune technology platform with a unique mixture of short protein fragments derived from the cancer-causing virus, HPV16.
  • PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Companys proprietary Versamune T-cell activating technology platform.

Innovia Medical Expands Single-Use Instrument Product Line into the US with Gynecology Product Cervical Rotating Biopsy Punch

Retrieved on: 
Wednesday, December 8, 2021
Medical Devices, Health, Biopsy, Reuters, University Hospital of Wales, American Society of Clinical Oncology, Engineering, Teaching hospital, Carbon, Health, Cervical cancer, Human papillomavirus infection, Starch, Cervix, Statistics, Woman, Gynaecology, HPV, Coronavirus, Titanium, Patient, Summit Medical Group, Medicine, PDO, Cancer, NHS, Cervical, Survival rate, Surgeon, Multimedia, Time, COVID-19, Quality, Program, Jaw, Harrogate District Hospital, International, Marketing, Diagnosis, STI, Hospital, Solution, Nursing, Society, International Journal of Cancer, National Health Service, Medical imaging, Birth control, Medical device, Pharmaceutical industry, INNOVIA MEDICAL, SUMMIT MEDICAL, DTR MEDICAL

The product leading the expansion is a gynecology product called the Cervical Rotating Biopsy Punch which supports urgently needed procedures like cancer diagnosis.

Key Points: 
  • The product leading the expansion is a gynecology product called the Cervical Rotating Biopsy Punch which supports urgently needed procedures like cancer diagnosis.
  • The Cervical Rotating Biopsy Punch has 2.8 times less of an environmental impact than other single-use products on the market like the metal Tischler Cervical Biopsy Punch and Baby Tischler Cervical Biopsy Punch.
  • We believe introducing the Cervical Rotating Biopsy Punch to the U.S. is a natural expansion of our Single-Use Instrument category.
  • To learn more about the Cervical Biopsy Rotating Punch or Innovia Medicals single-use instrument product line expansion into the U.S. visit www.innoviamedical.com .